Understanding how loss of the RB1 gene affects bladder cancer treatment
Therapeutic implication of RB1 loss in bladder cancer
This study is looking at how changes in a specific gene called RB1 might affect how bladder cancer responds to treatment, and it's designed to help doctors find better ways to treat patients with bladder cancer.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11032022 on NIH RePORTER |
What this research studies
This research focuses on the role of the RB1 gene in bladder cancer, particularly how its loss may influence treatment responses. Using advanced models like genetically engineered mice and organoids, the research aims to uncover the molecular mechanisms behind bladder cancer's behavior and its resistance to chemotherapy. The project is led by Dr. Qiang Li at Roswell Park Comprehensive Cancer Center, who is working to enhance his skills in cancer modeling and bioinformatics to better understand these processes. The findings could lead to improved treatment strategies for bladder cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are bladder cancer patients, especially those with RB1 mutations or those who have experienced chemotherapy resistance.
Not a fit: Patients with bladder cancer who do not have RB1 mutations or who are not undergoing chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for bladder cancer patients, particularly those with RB1 mutations.
How similar studies have performed: Other research has shown promising results in understanding the role of genetic mutations in cancer treatment responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Li, Qiang — Roswell Park Cancer Institute Corp
- Study coordinator: Li, Qiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.